Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Advanced Biliary Tract Carcinoma
NCT04003896Phase 2Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in biliary tract carcinoma (BTC), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Overall Response Rate up to 7 months. Started Sep 2021; status: terminated.
02
Drugs
abemaciclib
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT04003896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003896.